Trial Profile
A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Teslexivir (Primary)
- Indications Condylomata acuminata
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Anaconda Pharma; Aviragen Therapeutics; Vaxart
- 09 Nov 2018 According to a Vaxart media release, following the completion of the 3-month follow-up assessment in this study, analysis of the data showed there was no improvement compared to the topline results reported in June 2018.
- 18 Jul 2018 Status changed from active, no longer recruiting to completed.
- 04 Jun 2018 According to a Vaxart media release, patients are undergoing 3 months follow-up period to assess for condyloma recurrence.